Drug firm Lupin today reported 43.37 per cent decline in its consolidated net profit at Rs 202.76 crore for the first quarter ended June 30, hit by drop in sales in the US and Japan.
The company had posted a net profit of Rs 358.08 crore in the April-June quarter of 2017-18.
Income from operations declined to Rs 3,774.57 crore for the first quarter as compared with Rs 3,806.83 crore in the same period of the previous fiscal.
"The first quarter of FY2019 has been subdued, primarily on account of the US and Japan," Lupin Ltd Managing Director Nilesh Gupta said in a statement.
During the quarter, the company's North America sales declined to Rs 1,185.8 crore, as compared with Rs 1,499 crore in the same period of 2017-18.
Lupin's Japan sales stood at JPY 8,129 million during the first quarter ended June 30, as compared with JPY 8,585 million in the same period of the previous fiscal.
In India, the company's formulation sales grew by 30.7 per cent to Rs 1,192.4 crore during the period under review from the same period of the previous fiscal.
Shares of Lupin were trading 4.76 per cent down at Rs 823.90 apiece on the BSE today.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
